AUG 14, 2026 · JOURNAL ARTICLE
Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial
Signal Transduction and Targeted Therapy
Phase II RCT with clear dose-dependent weight loss versus placebo and metabolic benefits, but limited to 16 weeks and requiring Phase III confirmation before clinical adoption.
Reported
Primary endpoint: mean body weigh…−5.75%
Primary endpoint: mean body weigh…−9.73%
Primary endpoint: mean body weigh…−1.61%